At Investor Conferences


Picture EBD Group ChinaBio Partnering Forum 2022 650x100
Collaboration › Details

AstraZeneca–VaxEquity: saRNA technology, 202109– collab up to $195m + royalties for up to 26 drug targets


Period Period 2021-09-23
Organisations Partner, 1st AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Partner, 2nd VaxEquity Ltd. (VXT)
Products Product self-amplifying RNA technology (saRNA technology)
  Product 2 RNA-based therapeutic
Index term Index term VaxEquity–AstraZeneca: investment, 202109 equity investment by AstraZeneca in connection with strategic research collab
Person Person Pangalos, Menelas (AstraZeneca 201303 EVP Innovative Medicines + Early Development Biotech Unit)

VaxEquity Ltd.. (9/23/21). "Press Release: VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform". London.

VaxEquity receives upfront equity investment and up to $195 million and royalties in the mid-single digits per programme

VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform originating from Imperial College London, today announces a collaboration with AstraZeneca to progress the company’s platform technology through proof of concept to enable the development of multiple products. VaxEquity could receive development, approval and sales-based milestones totalling up to $195 million and royalties in the mid-single digits per drug target. VaxEquity also received an upfront equity investment from AstraZeneca and global life sciences investor Morningside Ventures.

The strategic, long-term research collaboration with AstraZeneca aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and has the option to collaborate with VaxEquity on up to 26 drug targets. VaxEquity’s modified saRNA platform uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level.

Michael Watson, Executive Chairman of VaxEquity, said, “We are delighted to collaborate with AstraZeneca given its strong track record in innovation and welcome them as a new investor. We are also grateful for the ongoing support of our existing investor, Morningside Group. With our self-amplifying RNA platform, we aim to underpin the next generation of RNA-delivered medicines enabling not only vaccines but also broad range of therapeutic applications.”

Professor Robin Shattock, Head of Immunology of Infection within the Department of Infectious Diseases at Imperial College London, and co-founder of VaxEquity, said, “We have all seen how technologies based around RNA have been fundamental to preventing ongoing severe disease and death in major global pandemics. The prospect of further therapeutic applications adds to this technology’s great potential.”

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said “This collaboration with VaxEquity adds a promising new platform to our drug discovery toolbox. We believe self-amplifying RNA, once optimised, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest.”

Professor Alice Gast, President of Imperial College London, said: “I am deeply proud of my colleagues’ work in pioneering self-amplifying RNA technology. This collaboration will help realise our ambition of building a lasting legacy from the great scientific advances Imperial made in this pandemic.”

The proprietary, flexible platform enables the simultaneous expression of a broad range of targets and immunomodulatory proteins that can be rapidly produced and delivered at scale. Using saRNA, rather than mRNA, means that a lower (1/3 to 1/10th) dose of RNA is required to provide greatly enhanced protein expression as the RNA replicates for longer post-administration. VaxEquity modifies the RNA to include elements (called ‘Innate Inhibitory Proteins’ or IIPs) that finely tune the innate immune response (based on interferons) preventing suppression of RNA replication and thereby maximizing protein expression by saRNA.

As part of this investment and collaboration, Tyrell Rivers and Anders Holmén from AstraZeneca will join VaxEquity’s Board as Investor Directors. Will West and Jason Dinges will represent Morningside. Charles Mallo will represent Imperial. Robin Shattock will remain on the Board, while Michael Watson will assume the role of Executive Chair.

Media contacts:


Michael Watson Executive Chairman

Scius Communications (for media)

Katja Stout

Daniel Gooch

About VaxEquity

VaxEquity is developing transformative RNA therapeutics and vaccines using its next generation self-amplifying RNA platform. The Company uses saRNA to provide extended duration of protein expression. This enables lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed and manufactured rapidly and at scale.

VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and Morningside and is led by a world class team who are pioneers in the field of RNA. The Company is collaborating with AstraZeneca to progress its platform across multiple disease areas.

To learn more about VaxEquity please visit and follow our LinkedIn.

About Morningside Group

Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific.

In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients.

Morningside’s focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and there is a plausible path forward in clinical development. Their mission is to contribute to making meaningful, positive impact on prevention or treatment of human disease and believe that so long as this is achieved, commercial success will follow.

About Imperial College London

Imperial College London is one of the world's great universities. The College's 20,000 students and 8,000 staff are working to solve to the biggest challenges in science, medicine, engineering and business. Imperial is the world's fifth most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. Imperial staff, students and alumni are working round-the-clock to combat COVID-19, and the institution is been at the forefront of coronavirus epidemiology, virology, vaccine development and diagnostics.

Record changed: 2022-01-02


Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group ChinaBio Partnering Forum 2022 650x300

» top